Loyal Valley Capital

Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.

Sinovent Inc. is a biopharmaceutical company established in 2016, with its headquarters in Suzhou, China, and additional offices in Beijing and Boston. The company focuses on developing innovative treatment methods through its advanced biotechnology platform and extensive management experience. Sinovent aims to address global healthcare challenges by combining expertise in science, management, and finance. Currently, it has 12 products in development, primarily targeting oncology, autoimmune diseases, and infectious diseases.

DP Technology is a global leader in the "AI for Science" research paradigm, where AI learns scientific principles and data, then tackles key challenges in scientific research and industrial R&D. DP's commitment to interdisciplinary research has led to the creation of the DP "Particle Universe", an array of pre-trained large science models designed to bridge foundational research with practical industrial applications. DP's software suite includes the Bohrium® Scientific Research Space, Hermite® Computational Drug Design Platform, RiDYMO® Dynamics Platform, and Piloteye® Battery Design Automation Platform. Together, these platforms form a robust foundation for industrial innovation and an open ecosystem for AI in science, fostering advancements in key areas such as drug discovery, energy, material science, and information technology.

Chabaidao is a tea drink brand that aims to create surprises through product development and trendy gameplay.

Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.

Beijing Surgerii Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive surgical robot systems in China. Founded in 2014 and based in Beijing, the company focuses on innovative technologies, particularly the next generation of flexible continuum robotic arms. Surgerii Technology aims to transform clinical practices through its single-hole and porous laparoscopic robot systems, enhancing the standard of care in minimally invasive surgeries. With a commitment to independent research and development, the company leverages its expertise in system design and integration to advance the medical equipment industry in China.

Bowang Pharmaceutical is an RNAi drug research and development platform focused on siRNA drug development.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

O-Net Technologies (Group) Limited is an investment holding company based in Shenzhen, China, specializing in the design, manufacture, and sale of optical networking components, modules, and subsystems for high-speed telecommunications and data communications systems. Founded in 2000, O-Net provides a diverse range of optical communication products, including amplifiers, couplers, connectors, and tunable filters, as well as data center solutions. Additionally, the company manufactures industrial application products such as fiber lasers, electronic cigarette accessories, and mobile phone parts. O-Net also engages in the production of automation equipment and offers coating solutions for consumer electronics. The company operates a research and development center in the United States and has a presence in China, Europe, North America, and other Asian countries. Since its listing on the Hong Kong Stock Exchange in 2010, O-Net has established itself as a key player in the high technology sector, particularly in optical networking and automation.

Jinyuansheng specializes in the development, smelting, and deep processing of energy metal mineral resources, particularly focusing on lithium-ion battery cathode precursor materials. The company is committed to the comprehensive utilization of metal resources and the recycling of power batteries and related materials. By leveraging advancements in science and technology, Jinyuansheng aims to create innovative materials that support energy efficiency and contribute to a more sustainable and environmentally friendly future.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, focused on discovering and developing therapeutics for unmet medical needs, particularly in respiratory viral infections and viral hepatitis. Founded in 2013, the company is dedicated to addressing global health challenges with its innovative products, which include AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences aims to establish itself as a leader in antiviral drug development through a commitment to scientific excellence and innovation.

Frontera Therapeutics is a company specializing in adeno-associated virus (AAV) gene therapy, focused on developing and commercializing cost-effective recombinant virus-based therapies. The company aims to create a scalable platform that produces high-quality, affordable rAAV therapies for a range of genetic disorders, including ophthalmic, liver, metabolic, and neuromuscular diseases. Frontera Therapeutics has a diverse product pipeline that encompasses multiple therapeutic areas, with various candidates at different stages of development. By prioritizing affordability and quality, the company seeks to enhance the lives of patients through innovative genetic therapies.

Alit Life Sciences is a supplier of instruments, equipment, and technical services tailored for the life sciences and biotechnology sectors. The company has developed a range of products, including its self-developed Countstar IC1000 cell analyzer, launched in 2011, along with several product series such as Biotech, Altair, Rigel, and Mira. Alit provides a comprehensive suite of laboratory instruments, testing reagents, and production equipment that supports customers from research and development through to production. Additionally, the company acts as a supplier of international biological equipment, ensuring that clients in the biotech and life sciences industries have access to a complete kit of essential supplies.

MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.

Chen Xianggui is a catering brand and servicer that makes Lanzhou ramen and snacks, braised beef skewers, mutton, and other products.

Peijie Hotpot operates a chain of authentic Chongqing spicy hotpot restaurants, focusing on delivering genuine culinary experiences to its customers. In addition to its dining services, the company offers catering management, fast-moving food services, and hotel management. Peijie Hotpot emphasizes cultural management and entertainment supervision, creating a comprehensive dining atmosphere that enhances customer engagement. Through its diverse offerings, the company aims to maintain high standards in both food quality and service, ensuring an enjoyable experience for patrons seeking authentic hotpot cuisine.

ABclonal Inc. is a life science research and diagnostic reagents provider based in Woburn, Massachusetts, founded in 2016. The company specializes in offering a variety of biological research agents and services, including next generation sequencing library preparation kits, molecular biology products, catalog antibodies, catalog proteins, ELISA kits, and western blot tools and reagents. In addition to its extensive product range, ABclonal provides customized services related to peptides, antibodies, and proteins. The company distributes its products through a network of distributors across Europe, Asia, North America, and Oceania, aiming to enhance the quality of life science research with its high-quality offerings.

Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.

Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company specializing in the development and sale of protein and peptide drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company focuses on therapeutic areas such as diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neuro-degenerative conditions. Sciwind's innovative drug candidates are particularly targeted at metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for healthcare professionals and their patients.

Leads Biolabs is a biotechnology company focused on developing innovative antibody-based therapeutics to address unmet medical needs in oncology and immunological diseases. Founded in 2014 and headquartered in China, the company has established a strong research and development pipeline featuring over ten projects centered on monoclonal and bispecific antibodies for cancer immunotherapy. By concentrating on tumor immunotherapy, Leads Biolabs aims to enhance treatment outcomes and access for patients globally, thereby improving their medical conditions and overall quality of life.

Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

JCET Group manufactures semiconductor products.

Hepagene Therapeutics is focused on developing innovative treatments for liver diseases. The company engages in research and development efforts aimed at addressing conditions such as non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection, and liver cancer. By concentrating on these critical areas, Hepagene Therapeutics seeks to provide effective pharmaceutical solutions that can significantly improve patient outcomes in the realm of liver health.

EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Xiaoxian Dun is a healthy food products company that develops products from bird's nests. The company focuses on researching and developing a way to make a bowl of bird's nests that are just as good as a stew pot's slow-cooked bird's nest so that more people can enjoy it. The company seeks to revive and expand the conventional bird's nest market.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to address unmet clinical needs in the treatment of ophthalmic diseases. The company boasts a portfolio of breakthrough technologies aimed at providing effective solutions for patients with rare eye conditions. Founded by prominent life sciences investors, Arctic Vision is led by an experienced team of industry veterans skilled in research and development as well as the commercialization of eye care products. Its commitment to advancing ophthalmic medicine positions it as a key player in both the Asian and global markets.

MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.

Regor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting oncology, metabolic diseases, and autoimmune diseases. Utilizing its proprietary CARD (Computer Accelerated Rational Discovery) platform, Regor integrates various scientific disciplines, including structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. This approach allows the company to efficiently produce both best-in-class and first-in-class therapeutic molecules. With a strong emphasis on scientific expertise, Regor Therapeutics aims to deliver clinically differentiated treatments that address unmet medical needs.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

CARsgen Therapeutics, Ltd. is a clinical-stage immunotherapy company based in Shanghai, China, focused on developing chimeric antigen receptor T-cell (CAR-T) therapeutics for various cancers, including liver, lung, stomach, and brain cancers. The company specializes in CAR-T technology that enables T cells to target and destroy cancer cells by recognizing specific cell surface proteins. Notably, CARsgen’s therapies are designed to treat late-stage hepatocellular carcinoma (HCC) and lung squamous cell carcinoma. The company has also made significant advancements in clinical trials, having completed the world's first dose-ascending injection tests for HCC and exclusive tests for glioblastoma multiforme (GBM) in China. CARsgen collaborates with institutions such as the Shanghai Cancer Institute and Shanghai Renji Hospital, and is supported by prominent venture capital funding, positioning it to introduce innovative cancer treatments both in China and globally.

Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.

Chinese sorghum spirit producer from Chongqing. Specializing in innovated light-aroma baijius with creative presentation.

Sinovent Inc. is a biopharmaceutical company established in 2016, with its headquarters in Suzhou, China, and additional offices in Beijing and Boston. The company focuses on developing innovative treatment methods through its advanced biotechnology platform and extensive management experience. Sinovent aims to address global healthcare challenges by combining expertise in science, management, and finance. Currently, it has 12 products in development, primarily targeting oncology, autoimmune diseases, and infectious diseases.

OBiO Technology is a biotechnology company specializing in gene therapy solutions. It offers contract research organization (CRO) services focused on the development of gene therapy vectors, gene function research, and drug target efficacy. The company also provides contract development and manufacturing organization (CDMO) services, which include process development, testing, and IND-CMC pharmaceutical research. Additionally, OBiO Technology supports the production of clinical samples under Good Manufacturing Practices (GMP) for genetic drug research and development. Through its comprehensive offerings, the company aims to advance the field of gene therapy and facilitate the development of innovative therapeutic solutions.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Heyuan Biotechnology is a biotechnology company focusing on the field of gene therapy services. They offer gene therapy vectors, gene function research, drug targets, and efficacy for the basic research of gene therapy research, among other services.

Hygeia Healthcare Group is a leading oncology-focused healthcare group in China. The company operates its own hospitals, provides third-party radiotherapy service, and manages partner hospitals. Its core business consists of 7 oncology hospitals and 3 managed hospitals in in 6 provinces in China. In addition, the company provides services to 15 hospital partners (including managed hospitals) in 9 provinces of China on its radiotherapy centers.

Beaver Education is an online education company focused on delivering high-quality teaching services for elementary and middle school students, as well as educational institutions. The company offers a range of products, including online subject training courses and personalized tutoring tools. Its platform features two key modules: a process evaluation module and a personalized learning module. Additionally, it includes a teaching management and quality monitoring module, which provides educators with essential management information and data analysis tools. This comprehensive approach aims to enhance the learning outcomes of students and support teachers in their daily management tasks.

Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.

Pop Mart International Group Ltd is a Chinese company specializing in the design, development, and retail of designer toys, particularly in the pop culture sector. The company has established a comprehensive operational platform that encompasses the entire industry chain of these collectibles. Pop Mart's products are marketed in various regions, including Mainland China, Hong Kong, Macao, Taiwan, and other international markets. The majority of its revenue is derived from retail sales through physical stores, complemented by sales from roboshops, wholesale distribution, and online platforms. Pop Mart is organized into two main segments: operations in Mainland China and operations in Hong Kong, Macao, Taiwan, and overseas markets.

Perfect Diary is an e-commerce-based cosmetic brand. The company is committed to exploring the trends in international cosmetics and the frontiers of fashion to provide easy-to-use cosmetics products for young Asian women.Perfect Diary is professional in branding and online traffic management. By launching co-branded cosmetic products with KOLs, idols and even some famous organizations like the British Museum

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

RemeGen, Ltd. is a biopharmaceutical company based in Yantai, Shandong Province, China, focused on addressing unmet medical needs for patients with life-threatening conditions. The company specializes in the research, development, manufacturing, and commercialization of innovative biologics, particularly monoclonal antibodies and antibody-drug conjugates. RemeGen's leading products include Telitacicept, aimed at treating systemic lupus erythematosus, and Disitamab Vedotin, designed for various cancers. The company’s therapeutic offerings target significant health issues, including autoimmune diseases, oncology, and ophthalmology. With operations in both China and the United States, RemeGen primarily generates its revenue from the Chinese market.

Kaishuo Jianggushi is a children's content provider. Also known as Kaishu Story, the brand is focusing on children’s stories with additional products such as audio series and online parenting courses.

Juvenile is a learning and counseling application for primary and secondary schools, mainly for 7-15 year olds. The application covers the knowledge points and exam focus of each subject in primary and secondary schools, and answers the test proposition in detail. The knowledge coverage can meet the needs of further studies, and can also help students to self-study after class. The app also provides students with effective learning method guidance, audio books and learning materials.

Akeso Biopharma, based in Zhongshan, China, operates as a contract research organization (CRO) specializing in the discovery and development of antibody and protein drugs. Founded in 2012, the company provides comprehensive CRO services to both domestic and international pharmaceutical clients, focusing on areas such as protein expression, antibody generation, assay development, and humanization. Akeso has developed an extensive biopharmaceutical research and development platform, with a robust product pipeline that includes over 30 drugs targeting cancers, autoimmune diseases, inflammation, and cardiovascular conditions. Among these, 17 drugs have progressed to clinical stages, including two first-in-class bi-specific antibody drugs. The company collaborates with various pharmaceutical firms to innovate and develop new drug candidates, establishing itself as a leader in the industry through its advanced facilities and expertise.

Mahua Fun Age, the largest drama agency in China, was founded in 2003 and has produced popular dramas and movies such as "Clown Loves Beauty", "Count of Mountain Wulong", "Dream of those Years", "Xialuo’s trouble", and "Donkey water". With a strong portfolio of over 20 high-quality original shows and intellectual properties, Mahua Fun Age has established a significant presence in the entertainment industry. In 2016 alone, the company organized more than 1,600 tour shows across China, showcasing its creativity and appeal to a wide audience.

Allist Pharmaceuticals is a pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, particularly in the area of cancer treatment. The company addresses unmet clinical needs within the global pharmaceutical market, emphasizing the importance of scientific and technological advancements to improve patient outcomes. Allist Pharmaceuticals is committed to creating safe and effective drugs that are backed by independent intellectual property rights, ensuring that their innovative therapies can meet the diverse needs of patients.

NetEase Cloud Music, established in 2013 and based in Hangzhou, China, specializes in online music streaming services through its mobile application. The platform enables users to access a wide variety of music and offers additional features, such as music discovery and social networking capabilities. As a subsidiary of NetEase, Inc., NetEase Cloud Music has grown to become a significant player in the Chinese music streaming market, catering to the evolving preferences of its audience while developing applications for smartphones to enhance user experience.

Juvenile is a learning and counseling application for primary and secondary schools, mainly for 7-15 year olds. The application covers the knowledge points and exam focus of each subject in primary and secondary schools, and answers the test proposition in detail. The knowledge coverage can meet the needs of further studies, and can also help students to self-study after class. The app also provides students with effective learning method guidance, audio books and learning materials.

InfiNovo, established in 2016, specializes in developing innovative healthcare solutions, particularly in the realm of chronic disease management. The company is dedicated to creating an accurate and affordable Continuous Glucose Monitoring (CGM) system for both Type 1 and Type 2 diabetes patients. InfiNovo's CGM aims to compete in the global market through its emphasis on accuracy, durability, and user-friendly design. Additionally, the company develops biosensors and application products that enhance diagnostic accuracy and treatment standards, providing technological tools that improve the management of chronic diseases.

EVE Energy Co., Ltd. is a leading manufacturer of lithium batteries based in Huizhou, China, established in 2001. The company specializes in the development and production of a wide range of lithium primary and lithium-ion batteries, including lithium thionyl chloride and lithium-manganese dioxide batteries. EVE Energy's products serve various applications, such as smart meters, intelligent security systems, and new energy vehicles. The company also provides advanced power systems for electric vehicles and energy storage solutions for residential and industrial use. As a national high-tech enterprise, EVE has made significant investments in battery technology and innovation, positioning itself as a global frontrunner in the lithium thionyl chloride battery market. With a commitment to high-quality manufacturing and service, EVE Energy continues to expand its presence in China, Hong Kong, Taiwan, the United States, and Europe.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

Jinfuzi is an online investment platform that offers a range of wealth management services, allowing users to invest in various financial products, including private equity, venture capital, trusts, and foreign funds. The platform is designed to assist investors in selecting investment portfolios that align with their return-risk preferences. Jinfuzi provides two primary mobile applications: Finance Port and Snowball, which facilitate access to a diversified selection of investment options. Through its comprehensive services, Jinfuzi aims to cater to the diverse needs of investors seeking to optimize their financial growth.

Wajijia Entertainment provides network and entertainment production services. Their businesses include producing television content and music videos that enable consumers to enjoy a variety of entertainment content and music.

InnoCare is a biopharmaceutical company based in China, focused on discovering, developing, and commercializing innovative treatments for cancer and autoimmune diseases. The company boasts a skilled scientific team with extensive experience in drug innovation from both the U.S. and China, supported by an accomplished Scientific Advisory Board comprised of experts from prominent universities, hospitals, and the pharmaceutical sector. InnoCare's product pipeline includes several key therapies, such as orelabrutinib, ibrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune disorders. The company is also dedicated to addressing autoimmune diseases linked to abnormal B-cell or T-cell functions, positioning itself as a leader in advancing medical treatments and tackling complex health challenges.

Dedao manufactures auto parts. Their products include inspection tools, towing hooks, waveform crash barriers, threshold stiffeners, and roller beams. They provide sales, research, and development services.

Immupeutics Medical Technology Co., Ltd. is a biomedical research company focused on the development of tumor immunotherapy. The firm specializes in creating immune cell therapy drugs aimed at treating various types of tumors and is committed to advancing companion diagnostic technology and immunological multi-omics technology. Through its research and development efforts, Immupeutics seeks to deliver innovative immune cell therapies and integrated treatment methods that enhance patient outcomes in cancer care.

ByteDance is a technology company that develops and operates a range of content platforms, most notably TikTok and Douyin. It aims to enhance user experiences through innovative technology, allowing individuals to connect, create, and consume content seamlessly. The company specializes in mobile applications that cater to online media, entertainment, and social networking, leveraging artificial intelligence to deliver personalized content that aligns with users' preferences. In addition to its flagship platforms, ByteDance provides tools that facilitate content creation and collaboration, reflecting its commitment to enriching lives through technology.

Linklogis Inc is a technology solution provider specializing in supply chain finance in China. The company develops a financial service platform that leverages big data, artificial intelligence, and blockchain technologies to facilitate direct connections between asset providers and funding sources. This enables small-sized companies to access financing more conveniently. Linklogis operates in two primary segments: Supply Chain Finance Technology Solutions and Emerging Solutions. The Supply Chain Finance Technology Solutions encompass products like Anchor Cloud and FI Cloud, while Emerging Solutions include offerings such as Crossborder Cloud and SME credit technology solutions. By focusing on practical applications and innovative technologies, Linklogis aims to enhance the efficiency of supply chain financial services in the market.

WeShare is a Chinese financial services provider that focuses on enhancing the capabilities of consumer financial institutions. The company facilitates access to customers, risk control, and funding for these institutions. By leveraging technology and data analysis, WeShare enables both onshore and offshore institutional investors to make secure and efficient investments in China's consumer finance sector. The firm is dedicated to developing advanced fintech capabilities and aims to foster collaboration and mutual benefits with industry partners.

Teligene Ltd. is a pharmaceutical research and development company based in Jiangsu, China, established in 2011. The company specializes in the development of small-molecule drugs, particularly innovative treatments for oncology. Teligene's focus is on the research, development, and industrialization of small molecule targeted anti-tumor drugs, utilizing advanced drug development technologies. The experienced management team is well-versed in contemporary trends and practices in drug development both domestically and internationally. Teligene aims to create original anti-tumor drugs with independent intellectual property rights, addressing emerging areas of research and development in the pharmaceutical field.

Chaodian Culture is a brokerage firm that provides in cultural brand of the bilibili video screen network.

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the research, development, production, and commercialization of biologics, particularly monoclonal antibody (mAb) biosimilars and novel therapies. Founded in 2010, the company focuses on oncology and autoimmune diseases, offering products such as HLX01, a biosimilar for treating non-Hodgkin lymphoma. Henlius is actively advancing its pipeline, with multiple products under review for regulatory approval, alongside conducting numerous clinical studies for various therapies. The company collaborates with partners, including agreements to develop treatments for COVID-19 and eye diseases. Shanghai Henlius Biotech is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, established in 2009, and operates out of the Shanghai Caohejing High-Technology Park.

Sinovent Inc. is a biopharmaceutical company established in 2016, with its headquarters in Suzhou, China, and additional offices in Beijing and Boston. The company focuses on developing innovative treatment methods through its advanced biotechnology platform and extensive management experience. Sinovent aims to address global healthcare challenges by combining expertise in science, management, and finance. Currently, it has 12 products in development, primarily targeting oncology, autoimmune diseases, and infectious diseases.

Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic therapies aimed at treating cancer. Immune-Onc Therapeutics focuses on the tumor microenvironment and immune suppressive pathways, utilizing advanced scientific insights to create novel immuno-oncology products. The company employs a targeted approach to develop first-in-class therapeutic antibodies that disarm immune suppression in tumors, thereby enhancing the immune response against cancer. Through its differentiated pipeline, Immune-Onc Therapeutics aims to provide new treatment options for cancer patients, addressing critical needs in the field of immunology and oncology.

Innomed medical niche markets' products and services. They continue to provide consumers with helpful advice and assistance in their department so that they can carry out their care as as possible. For global medical startup firms, they complete late-stage commercialization partners.

Kaishuo Jianggushi is a children's content provider. Also known as Kaishu Story, the brand is focusing on children’s stories with additional products such as audio series and online parenting courses.

The #1 international kindergarten in Beijing

Didi Chuxing, founded in 2012 in Beijing, is a leading mobile transportation platform providing app-based services such as taxi hailing, private car-hailing, social ride-sharing, car rental, and enterprise solutions. With over 450 million users and daily orders reaching 25 million, Didi offers a variety of mobility options to optimize resource allocation through big data-driven algorithms. The company aims to address transportation, environmental, and employment challenges by collaborating with communities and partners. Acquiring Uber China in 2016, Didi has over 21 million drivers and car owners on its platform, generating income while offering convenient transportation solutions to users worldwide.

GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014 that specializes in gene research and the development of advanced cancer diagnostic solutions. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which are used for companion diagnostics, genetic profiling, prognosis, and monitoring of various solid tumors, including lung, colorectal, liver, and breast cancers. GeneCast provides non-invasive and precise tumor diagnoses and personalized treatment guidance, leveraging high-throughput sequencing and bioinformatics. The company collaborates with hospitals and research institutions to enhance cancer treatment and genetic testing, aiming to improve patient outcomes and quality of life. GeneCast is also focused on advancing its research and clinical trials while expanding its distribution channels.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Established in October 2013, Sugarman Media is a comprehensive film and television organization integrating film and television planning, production and distribution, post-production, entertainment marketing, and performing arts brokerage. The company's main business is the production of online dramas, and has produced two explosive works "The Hurry" and "The Best of Us". The company has the ability to continue to produce high-quality content, and will be committed to creating high-quality film and television IP through a series of plays in the future.

The Child Academy provides a developmentally appropriate learning environment where all children's emotional, social, physical, and intellectual needs are satisfied in a supportive, artistic environment. They employ a combination of play-based and literacy activities to build self-esteem, critical thinking, problem solving, and management skills in an atmosphere that incorporates scheduled, routine, and open discovery activities.

Leading financial and insurance technology company in China

Phyplus Inc., founded in 2015 and based in Shanghai, China, specializes in designing high-performance, low-power communication chips. The company focuses on developing mixed-signal integrated circuits and system-on-chips tailored for Internet of Things (IoT) applications. Phyplus is particularly known for its low-power Bluetooth solutions, which emphasize minimal power consumption, high integration, and competitive price/performance ratios. Through its innovative approach, Phyplus aims to enhance the capabilities of smart terminal devices in the expanding IoT market.

Gaosi Education Group is a Chinese educational institution specializing in extracurricular tutoring for middle and primary school students. Founded in December 2009, it is headquartered in Beijing's Haidian District. The group focuses on gifted education, offering tailored courses for students from primary through junior high school. It features personalized one-on-one teaching centers and emphasizes mathematics competitions as a key component of its curriculum. With nearly 10,000 students enrolled, Gaosi Education Group employs around 100 full-time teachers and staff dedicated to teaching and research.

Linklogis Inc is a technology solution provider specializing in supply chain finance in China. The company develops a financial service platform that leverages big data, artificial intelligence, and blockchain technologies to facilitate direct connections between asset providers and funding sources. This enables small-sized companies to access financing more conveniently. Linklogis operates in two primary segments: Supply Chain Finance Technology Solutions and Emerging Solutions. The Supply Chain Finance Technology Solutions encompass products like Anchor Cloud and FI Cloud, while Emerging Solutions include offerings such as Crossborder Cloud and SME credit technology solutions. By focusing on practical applications and innovative technologies, Linklogis aims to enhance the efficiency of supply chain financial services in the market.

Pipilu is a company dedicated to providing entertainment content and products specifically designed for children in China. It focuses on producing original publishing materials, movies, animations, and various consumer products. By prioritizing quality in its offerings, Pipilu aims to deliver engaging and entertaining experiences that cater to the interests and needs of young audiences.

Established in 2013, Studio 9 is a leading original animation IP creation company. It has the highest-yield production line of comics and 2D & 3D animation in China. The company has built its IP production committee to further expand the value of its IP in animation, movies and games. It has also successfully created China's first action animation IP " The Outcast ", and hot IPs such as “No”, “Heaven to Earth”, etc.

Avary Holding is a joint-stock firm that is involved in printed circuit board design, research, development, manufacturing, and sales. The primary products of the company are communication boards, boards for computers and consumer electronics, and other boards. Additionally, these goods are primarily used in downstream goods including mobile phones, network equipment, tablets, wearable tech, notebook computers, servers, storage, automotive electronics, and others. Both domestically and internationally, the company distributes its goods.

Beijing Haixue Education Technology Co., Ltd. operates the Haixue platform, which provides employment and career development solutions tailored for students and professionals in China. The platform utilizes advanced technology, including artificial intelligence and big data analysis, to create personalized learning experiences and recommend relevant knowledge points. Haixue offers a range of skill training programs across various fields, such as construction, accounting, law, and health. By incorporating live lectures and high-definition broadcasting into its training system, the company enhances the learning experience and maximizes the workplace value of its users. Through its innovative approach, Haixue aims to facilitate hassle-free learning and professional development.

ECNUAS is a global private boarding institution that caters to students from kindergarten through high school. The primary objective of the school is to establish a Chinese educational model that has a significant impact on the world. It combines the finest elements of both Eastern and Western educational philosophies and methodologies, while also identifying and leveraging high-quality educational resources at local, national, and international levels.

iDreamSky Technology is a Shenzhen-based company founded in 2009, recognized as a leading smartphone application developer in China. The company specializes in the game publishing market, offering a diverse portfolio that includes role-playing games, endless running games, matching puzzle games, and casual competition games. iDreamSky operates a digital entertainment platform that focuses on providing game and information services, catering to both developers and gamers. The company has established significant partnerships with major clients such as Lenovo, China Telecom, and HTC. In 2011, it received a seed investment to launch Skynet, a one-stop solution aimed at helping game developers expand and establish their presence in the Chinese market.

Xinshixiang is a well-known brand in the content field which has extended from textual content manufacturing to famous events. The company's platform provides contents including personalized recommendation, emotional companionship, value puzzlement solutions, enabling the young generation to achieve self-worth through reading.

Luogic Thinking is China’s #1 online producer of educational podcasts.

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in Shanghai, China, focusing on the discovery, development, and commercialization of innovative drugs. The company operates in various therapeutic areas, including oncology, metabolic disorders, autoimmune diseases, and neurologic conditions. Junshi's notable products include JS001, a recombinant humanized anti-PD-1 monoclonal antibody marketed as TUOYIR for several cancers, and UBP1211, a biosimilar of Humira currently in Phase I clinical trials for rheumatoid arthritis and related conditions. Additionally, the company is advancing other drug candidates, such as JS002, a monoclonal antibody for hyperlipidemia, and several others in early-phase trials targeting various diseases. Junshi has established collaborations with leading pharmaceutical companies, including Eli Lilly and Merck, to develop therapeutic antibodies and explore new treatment combinations. Founded in 2012, Shanghai Junshi Biosciences is committed to addressing unmet medical needs through its extensive research and development initiatives.

China Mercy Health Group, founded by Liu Xiaocheng, focuses on enhancing the operational efficiency of medical institutions in China. Originating from the TEDA International Cardiovascular Hospital, which is recognized as a top-tier cardiovascular facility, the group offers a comprehensive range of services. These include hospital architecture and design, management consultancy, training for hospital staff, and procurement and logistics for medical devices and drugs. By providing these specialized services, China Mercy Health Group aims to create healthier environments for patients and improve the overall quality of healthcare in the region.

Sound Solutions, a subsidiary of [Dover Corporation](/organization/dover)'s Knowles Electronics and formerly owned by [NXP](/organization/nxp), manufactures speakers and receivers for cell phones and other electronic devices.

Wenzhou Kangning Hospital Co Ltd is a specialized mental health center in China that focuses on providing comprehensive psychiatric care and elderly rehabilitation services. The hospital offers a range of services, including forensic psychiatry, women's psychiatry, addiction treatment, geriatric psychiatry, and mental health services. Additionally, it features specialized clinics for depression and sleep disorders, as well as a dedicated center for child and adolescent psychology. The hospital also utilizes teleconsultation to enhance accessibility to its services. Revenue is primarily generated through the operation of its own healthcare facilities, along with other related business activities, reflecting its commitment to addressing diverse mental health needs in the community.

Linklogis Inc is a technology solution provider specializing in supply chain finance in China. The company develops a financial service platform that leverages big data, artificial intelligence, and blockchain technologies to facilitate direct connections between asset providers and funding sources. This enables small-sized companies to access financing more conveniently. Linklogis operates in two primary segments: Supply Chain Finance Technology Solutions and Emerging Solutions. The Supply Chain Finance Technology Solutions encompass products like Anchor Cloud and FI Cloud, while Emerging Solutions include offerings such as Crossborder Cloud and SME credit technology solutions. By focusing on practical applications and innovative technologies, Linklogis aims to enhance the efficiency of supply chain financial services in the market.

Bilibili Inc. is an online entertainment platform based in Shanghai, China, that caters primarily to the younger generations. Founded in 2009, it began as a community focused on anime, comics, and gaming (ACG), but has since broadened its offerings to include a wide variety of content such as videos, live broadcasting, and mobile games. The platform emphasizes high-quality content and fosters strong emotional connections among its users, creating a vibrant community. Bilibili generates revenue through multiple channels, including advertising, gaming, live streaming, value-added services, and e-commerce. The company has also formed a strategic collaboration with Tencent for sharing and operating anime and games, enhancing its content library and user experience.